Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김현영 | - |
dc.date.accessioned | 2019-12-09T06:43:04Z | - |
dc.date.available | 2019-12-09T06:43:04Z | - |
dc.date.issued | 2018-09 | - |
dc.identifier.citation | MOLECULAR NEUROBIOLOGY, v. 55, no. 9, page. 7153-7163 | en_US |
dc.identifier.issn | 0893-7648 | - |
dc.identifier.issn | 1559-1182 | - |
dc.identifier.uri | https://link.springer.com/article/10.1007%2Fs12035-018-0910-6 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/120121 | - |
dc.description.abstract | In patients with stroke and neurodegenerative diseases, overactivation of poly(ADP-ribose) polymerase-1 (PARP-1) causes harmful effects by inducing apoptosis, necrosis, neuroinflammation, and immune dysregulation. The current study investigated the neuroprotective effect of a novel PARP-1 inhibitor, JPI-289, in an animal model of ischemic stroke. A transient middle cerebral artery occlusion (tMCAO, 2 h) model was used to determine the therapeutic effect and the most effective dose and time window of administration of JPI-289. We also investigated the long-term outcomes of treatment with JPI-289 by diffusion-weighted imaging (DWI) and fluid-attenuated inversion recovery (FLAIR) MRI and by measuring neurological function at 24 h, 7 days, and 28 days after MCAO. The most effective dose and time window of administration of JPI-289 was 10 mg/kg administered 2 h after MCAO with reperfusion. Twenty-four hours after MCAO, infarct volume was reduced by 53% and the number of apoptotic cells was reduced by 56% compared with control. JPI-289 also reduced infarct volume by 16% in the permanent MCAO model. In an MRI-based study, initial infarct volume, as measured using DWI, was similar in the control and JPI-289-treated groups. However, infarct volume and brain swelling were significantly reduced in the group treated with JPI-289 (2 h) at 24 h and 7 days after MCAO. Neurological functions also improved in the group treated with JPI-289 (2 h) until 28 days after MCAO. Inhibition of PARP-1 has neuroprotective effects (reduction of infarct volume and brain swelling) in both tMCAO and pMCAO models of ischemic stroke. | en_US |
dc.description.sponsorship | This study was funded by grant of the Korea Drug Development Fund (KDDF-201410-08) and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (A100453) for the clinical development of JPI-289. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | SPRINGER | en_US |
dc.subject | Ischemic stroke | en_US |
dc.subject | PARP-1 | en_US |
dc.subject | JPI-289 | en_US |
dc.subject | Neuroprotection | en_US |
dc.title | Early Treatment with Poly(ADP-Ribose) Polymerase-1 Inhibitor (JPI-289) Reduces Infarct Volume and Improves Long-Term Behavior in an Animal Model of Ischemic Stroke | en_US |
dc.type | Article | en_US |
dc.relation.no | 9 | - |
dc.relation.volume | 55 | - |
dc.identifier.doi | 10.1007/s12035-018-0910-6 | - |
dc.relation.page | 7153-7163 | - |
dc.relation.journal | MOLECULAR NEUROBIOLOGY | - |
dc.contributor.googleauthor | Kim, Youngchul | - |
dc.contributor.googleauthor | Kim, Young Seo | - |
dc.contributor.googleauthor | Kim, Hyun Young | - |
dc.contributor.googleauthor | Noh, Min-Young | - |
dc.contributor.googleauthor | Kim, Ji Young | - |
dc.contributor.googleauthor | Lee, Young-Jun | - |
dc.contributor.googleauthor | Kim, Jeongmin | - |
dc.contributor.googleauthor | Park, Jiseon | - |
dc.contributor.googleauthor | Kim, Seung Hyun | - |
dc.relation.code | 2018000380 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | hyoungkim1 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.